Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Quality of Life Related Response to Treatment in Anemic Cancer Patients Receiving Recormon and Efficacy of the Drug Dosage 30,000 IU Once Weekly in Patients With Lymphoproliferative Disorders

NCT00776425 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00776425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00776425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Quality of Life Related Response to Treatment in Anemic Cancer Patients Receiving Recormon and Efficacy of the Drug Dosage 30,000 IU Once Weekly in Patients With Lymphoproliferative Disorders
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2007
Completion date
November 30, 2012
Enrollment
117 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

anemia